Credit Suisse’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Credit Suisse’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-19	Closed	–	–	4363
2022 Q2	$0	Buy	+19	New	+$54	﹤0.01%	4405
2015 Q3	–	Sell	-860	Closed	-$543K	–	4522
2015 Q2	$543K	Buy	860 +756	+727%	+$402K	﹤0.01%	3660
2015 Q1	$53K	Sell	104 -488	-82%	-$246K	﹤0.01%	4278
2014 Q4	$317K	Buy	592 +467	+374%	+$210K	﹤0.01%	4022
2014 Q3	$188K	Buy	125 +35	+39%	+$50.7K	﹤0.01%	4155
2014 Q2	$124K	Sell	90 -295	-77%	-$342K	﹤0.01%	4501
2014 Q1	$535K	Sell	385 -13	-3%	-$15.1K	﹤0.01%	3658
2013 Q4	$395K	Buy	398 +145	+57%	+$150K	﹤0.01%	3905
2013 Q3	$265K	Sell	253 -29	-10%	-$31K	﹤0.01%	3854
2013 Q2	$306K	Buy	+282	New	+$314K	﹤0.01%	3617

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Credit Suisse's VIRX Position: Q3 2022 in Review

Credit Suisse sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2022, closing a stake of 19 shares.

Credit Suisse first reported a position in VIRX in Q2 2013 and held it in 10 quarters. The position peaked at $543K in Q2 2015. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2022.

Credit Suisse reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 19 Viracta Therapeutics, Inc. Common Stock shares in Q3 2022.
Credit Suisse first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 10 quarters.
Credit Suisse's Viracta Therapeutics, Inc. Common Stock position peaked at $543K in Q2 2015.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.